$KPRX
KIORA PHARMACEUTICALS INC

2021 Q4 Form 10-Q Financial Statement

#000141057821000215 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.379M $1.339M $1.021M
YoY Change -8.95% 31.07% -2.73%
% of Gross Profit
Research & Development $1.002M $1.628M $985.9K
YoY Change -0.83% 65.18% -59.09%
% of Gross Profit
Depreciation & Amortization $11.04K $4.807K $2.388K
YoY Change 21.85% 101.3% -76.12%
% of Gross Profit
Operating Expenses $1.905M $2.967M $2.007M
YoY Change -24.58% 47.82% -41.82%
Operating Profit -$2.967M -$2.007M
YoY Change 47.82%
Interest Expense -$3.830K $260.00 $330.00
YoY Change -3.53% -21.21% -98.35%
% of Operating Profit
Other Income/Expense, Net $259.00 $331.00
YoY Change -21.75%
Pretax Income -$5.946M -$2.967M -$2.007M
YoY Change 147.38% 47.83% -41.49%
Income Tax -$192.6K
% Of Pretax Income
Net Earnings -$5.754M -$2.967M -$2.007M
YoY Change 138.17% 47.83% -41.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29 -$0.44
Diluted Earnings Per Share -$403.1K -$0.29 -$0.44
COMMON SHARES
Basic Shares Outstanding 12.65M 10.27M 4.548M
Diluted Shares Outstanding 10.27M 4.548M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.855M $11.11M $2.931M
YoY Change 562.46% 278.9% 19.65%
Cash & Equivalents $7.855M $11.11M $2.976M
Short-Term Investments
Other Short-Term Assets $606.5K $341.6K $563.5K
YoY Change 34.91% -39.37% -14.62%
Inventory
Prepaid Expenses $606.5K
Receivables
Other Receivables
Total Short-Term Assets $8.991M $11.87M $3.498M
YoY Change 420.84% 239.38% 12.46%
LONG-TERM ASSETS
Property, Plant & Equipment $74.00K $78.83K $11.25K
YoY Change 142.1% 600.74% -43.75%
Goodwill $0.00 $3.485M
YoY Change -100.0%
Intangibles $10.77M $9.711M
YoY Change 10.67%
Long-Term Investments
YoY Change
Other Assets $42.96K $44.25K $98.03K
YoY Change -24.72% -54.86% 40.04%
Total Long-Term Assets $11.14M $13.62M $5.748M
YoY Change -17.06% 137.03% -0.22%
TOTAL ASSETS
Total Short-Term Assets $8.991M $11.87M $3.498M
Total Long-Term Assets $11.14M $13.62M $5.748M
Total Assets $20.13M $25.49M $9.245M
YoY Change 32.81% 175.75% 4.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $160.6K $424.9K $59.53K
YoY Change -63.06% 613.74% -94.44%
Accrued Expenses $1.330M $1.389M $870.7K
YoY Change 3.17% 59.57% -21.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.610M $1.959M $930.2K
YoY Change -9.18% 110.6% -57.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $278.2K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $3.140M $5.457M $1.710M
YoY Change -41.63% 219.15% 41.32%
Total Long-Term Liabilities $3.942M $6.186M $1.988M
YoY Change -38.27% 211.15% 64.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.610M $1.959M $930.2K
Total Long-Term Liabilities $3.942M $6.186M $1.988M
Total Liabilities $5.551M $8.145M $3.284M
YoY Change -31.95% 148.05% -10.28%
SHAREHOLDERS EQUITY
Retained Earnings -$120.9M -$116.4M
YoY Change 11.58%
Common Stock $126.6K $126.2K
YoY Change 127.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.58M $17.35M $5.961M
YoY Change
Total Liabilities & Shareholders Equity $20.13M $25.49M $9.245M
YoY Change 32.81% 175.75% 4.23%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$5.754M -$2.967M -$2.007M
YoY Change 138.17% 47.83% -41.49%
Depreciation, Depletion And Amortization $11.04K $4.807K $2.388K
YoY Change 21.85% 101.3% -76.12%
Cash From Operating Activities -$3.198M -$2.270M -$5.608M
YoY Change 87.07% -59.52% 180.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$93.16K $0.00
YoY Change -58.48%
Cash From Investing Activities -$93.15K $0.00
YoY Change -61.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 65.91K 9.756M 4.780M
YoY Change -69.77% 104.13% -23997.5%
NET CHANGE
Cash From Operating Activities -3.198M -2.270M -5.608M
Cash From Investing Activities -93.15K 0.000
Cash From Financing Activities 65.91K 9.756M 4.780M
Net Change In Cash -3.225M 7.486M -828.2K
YoY Change 85.79% -1003.92% -59.0%
FREE CASH FLOW
Cash From Operating Activities -$3.198M -$2.270M -$5.608M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$3.198M -$2.270M
YoY Change 89.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10265108
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4547524
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8101004
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4536014
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12619256
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5556394
dei Entity Central Index Key
EntityCentralIndexKey
0001372514
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36672
dei Entity Registrant Name
EntityRegistrantName
KIORA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0443284
dei Entity Address Address Line1
EntityAddressAddressLine1
1371 East 2100 South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Salt Lake City
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84105
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
788-8869
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
KPRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12653054
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11106927
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1185677
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
341629
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
449569
CY2021Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
421463
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
90975
CY2021Q3 us-gaap Assets Current
AssetsCurrent
11870019
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1726221
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78833
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30566
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
45000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
45000
CY2021Q3 us-gaap Goodwill
Goodwill
3484607
CY2020Q4 us-gaap Goodwill
Goodwill
3484607
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9711414
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9730164
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
259217
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
83928
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44249
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
57073
CY2021Q3 us-gaap Assets
Assets
25493339
CY2020Q4 us-gaap Assets
Assets
15157559
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
424889
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
434763
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1389311
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1289261
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
144742
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
48303
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1958942
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1772327
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5342950
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5342950
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
728926
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
728926
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
278190
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
114475
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35625
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6186351
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6385691
CY2021Q3 us-gaap Liabilities
Liabilities
8145293
CY2020Q4 us-gaap Liabilities
Liabilities
8158018
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
41
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12619256
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5556394
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
126193
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
55564
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
133637500
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
115283572
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116355777
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108338834
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-59870
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-802
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
17348046
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6999541
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25493339
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15157559
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1628467
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
985880
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4348631
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2555035
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1338616
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1021325
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3944624
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3144255
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
2967083
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2007205
us-gaap Operating Expenses
OperatingExpenses
8293255
us-gaap Operating Expenses
OperatingExpenses
5699290
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2967083
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2007205
us-gaap Operating Income Loss
OperatingIncomeLoss
-8293255
us-gaap Operating Income Loss
OperatingIncomeLoss
-5699290
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
278190
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
259
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
331
us-gaap Investment Income Interest
InvestmentIncomeInterest
841
us-gaap Investment Income Interest
InvestmentIncomeInterest
23115
us-gaap Interest Expense
InterestExpense
2719
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
259
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
331
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
276312
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23115
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2966824
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2006874
us-gaap Net Income Loss
NetIncomeLoss
-8016943
us-gaap Net Income Loss
NetIncomeLoss
-5676175
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10265108
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4547524
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8101004
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4536014
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2966824
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2006874
us-gaap Net Income Loss
NetIncomeLoss
-8016943
us-gaap Net Income Loss
NetIncomeLoss
-5676175
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-44734
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17110
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-59068
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16944
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3011558
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2023984
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8076011
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5693119
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
10453787
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
149469
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
993666
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
44734
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2966824
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
17348046
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
7797604
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
187733
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
17110
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2006874
us-gaap Net Income Loss
NetIncomeLoss
-5676175
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4501313
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
16944
us-gaap Net Income Loss
NetIncomeLoss
-5676175
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
5961353
us-gaap Net Income Loss
NetIncomeLoss
-8016943
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
5961353
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6999541
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
629306
kprx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
50001
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
993666
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
59068
us-gaap Net Income Loss
NetIncomeLoss
-8016943
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
17348046
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6622455
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
530704
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
498687
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34260
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24343
kprx Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
133514
kprx Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
124896
us-gaap Share Based Compensation
ShareBasedCompensation
629306
us-gaap Share Based Compensation
ShareBasedCompensation
530704
kprx Expiration Of Prepaid Agreement
ExpirationOfPrepaidAgreement
159848
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-107940
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
202909
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
335096
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-2303
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-12826
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-16369
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9875
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-150755
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-133514
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-124896
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
100050
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-311430
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7477532
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5607702
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63865
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-63865
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17745207
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4501313
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
278190
kprx Cash Outflow From Loan Forgiveness
CashOutflowFromLoanForgiveness
278190
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50001
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17517018
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4779503
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-54371
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-17164
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9921250
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-845363
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1230677
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3821712
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11151927
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2976349
kprx Stock Issued During Period Value Conversion Of Series C Preferred Stock
StockIssuedDuringPeriodValueConversionOfSeriesCPreferredStock
8525
kprx Grant Of Restricted Stock Awards
GrantOfRestrictedStockAwards
490
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization, Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 5, 2021, Kiora Pharmaceuticals, Inc. (formerly known as EyeGate Pharmaceuticals, Inc.) (“Kiora” or the “Company”) filed with the Secretary of State of the State of Delaware, a Certificate of Ownership and Merger, merging its wholly-owned Delaware subsidiary, Kiora Pharmaceuticals, Inc., (incorporated in October 2021) into the Company and amending the Company's certificate of incorporation to change its name to “Kiora Pharmaceuticals, Inc.” effective November 8, 2021 (the “Name Change”). The Company also amended and restated its bylaws to reflect the change to the Company's name (the “Bylaws Amendment”). The Name Change and the Bylaws Amendment each became effective on November 8, 2021. The Company’s common shares commenced trading on the Nasdaq Capital Market under the new ticker symbol "KPRX" and a new CUSIP number (49721T101) effective at the market open on November 8, 2021. Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of 2020, Kiora acquired Panoptes Pharma Ges.m.b.H. (“Panoptes”) adding to its pipeline KIO-101(formerly known as PP-001), a next-generation, non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”), with what Kiora believes to be a best-in-class picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. KIO-101 has been developed in two clinical-stage ophthalmic formulations: an intravitreal injection for inflammatory diseases of the eye including posterior uveitis, and a novel nano carrier technology eye drop for ocular surface diseases such as dry eye disease. Other administration routes are also in development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Kiora is developing KIO-201(formerly known as Ocular Bandage Gel or “OBG”), a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity. KIO-201, with unique properties that help hydrate and protect the ocular surface, is in clinical evaluation for patients undergoing photorefractive keratectomy (“PRK”) surgery for corneal wound repair after refractive surgery and patients with punctate epitheliopathies (“PE”) as a result of dry eye. A type-B meeting was held with the U.S. Food and Drug Administration’s (“FDA”) Center for Drug Evaluation and Research (“CDER”) division during the first quarter of 2021 to discuss eligibility of continuing KIO-201 clinical studies as a drug. As a result, development of KIO-201 has shifted from a medical device to a drug, which allows for reimbursement under Medicare Part D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its inception, Kiora has devoted substantially all of its efforts to business planning, research and development, and raising capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The accompanying Condensed Consolidated Financial Statements have been prepared assuming that Kiora will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2021, Kiora had unrestricted Cash and Cash Equivalents of $11.107 million, and an Accumulated Deficit of $116.356 million. Kiora has incurred losses and negative cash flows since inception, and future losses are anticipated. Based on its cash on hand at September 30, 2021, the Company anticipates having sufficient cash to fund planned operations into the second half of 2022, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for the need to raise additional capital to complete development of its products. To continue development, Kiora will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although historically the Company has been successful at raising capital, most recently raising net proceeds of approximately $9.8 million in a registered direct offering that closed on August 11, 2021, additional capital may not be available on terms favorable to Kiora, if at all. On May 13, 2019, the SEC declared effective Kiora’s registration statement on Form S-3, registering a total of $50,000,000 of its securities for sale to the public from time to time in what is known as a “shelf offering”. The Company does not know if any future offerings, including offerings pursuant to its shelf registration statement, will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company’s recurring losses from operations have caused management to determine there is substantial doubt about the Company’s ability to continue as a going concern. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</p>
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11107000
CY2019Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
50000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for its clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.</p>
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
9536000
CY2020Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
9536000
CY2021Q3 kprx Intangible Assets And In Process Research And Development
IntangibleAssetsAndInProcessResearchAndDevelopment
175000
CY2020Q4 kprx Intangible Assets And In Process Research And Development
IntangibleAssetsAndInProcessResearchAndDevelopment
194000
kprx Related Party Transactions Number Of Vendors
RelatedPartyTransactionsNumberOfVendors
1
kprx Related Party Transactions Number Of Consultants
RelatedPartyTransactionsNumberOfConsultants
4
kprx Related Party Transactions Number Of Vendors
RelatedPartyTransactionsNumberOfVendors
2
kprx Related Party Transactions Number Of Consultants
RelatedPartyTransactionsNumberOfConsultants
7
CY2021Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
23277
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
42823
CY2020Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
79231
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
79223
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7300297
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3871510
CY2021Q3 kprx Money Market Funds Fair Value
MoneyMarketFundsFairValue
5343000
CY2020Q4 kprx Money Market Funds Fair Value
MoneyMarketFundsFairValue
5343000
CY2021Q3 kprx Contingent Consideration Funds Fair Value
ContingentConsiderationFundsFairValue
1710000
us-gaap Increase Decrease In Fair Value Adjustments On Assets And Liabilities Carried At Fair Value Under Fair Value Option
IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
0
CY2020 us-gaap Increase Decrease In Fair Value Adjustments On Assets And Liabilities Carried At Fair Value Under Fair Value Option
IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
187211
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123540
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
108378
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
92974
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78833
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30566
CY2021Q3 us-gaap Depreciation
Depreciation
4807
CY2020Q3 us-gaap Depreciation
Depreciation
2388
us-gaap Depreciation
Depreciation
15510
us-gaap Depreciation
Depreciation
5593
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
764306
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
629465
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138273
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
328420
CY2021Q3 kprx Clinical Trials Current
ClinicalTrialsCurrent
485733
CY2020Q4 kprx Clinical Trials Current
ClinicalTrialsCurrent
203646
CY2021Q3 kprx Consulting Expenses Current
ConsultingExpensesCurrent
999
CY2020Q4 kprx Consulting Expenses Current
ConsultingExpensesCurrent
125913
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1817
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1389311
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1289261
CY2020Q2 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
278000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6250
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6250
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18750
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18750
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
500000
CY2020Q1 us-gaap Share Price
SharePrice
10.00
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4500000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1531101
CY2021Q1 kprx Class Of Warrant Or Right Number Of Warrant Issued
ClassOfWarrantOrRightNumberOfWarrantIssued
1531101
CY2021Q1 kprx Share Purchase Price Of Common Stock And Warrant
SharePurchasePriceOfCommonStockAndWarrant
5.225
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8000000.0
CY2021Q1 kprx Warrant Exercise Price Per Share Subject To Adjustment
WarrantExercisePricePerShareSubjectToAdjustment
5.225
CY2021Q1 kprx Warrant Term
WarrantTerm
P5Y
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4668844
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.3025
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
233442
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.8781
CY2021Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9800000
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
59414
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
246893
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.90
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
265865
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
13876
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
20.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
26833
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.51
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
472049
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M19D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
200500
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M19D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
472049
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
12.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y11M19D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
174175
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.42
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M19D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
93165
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
17114
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
10.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3333
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.20
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
246893
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M15D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
138317
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
32.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y18D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
246893
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
20.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M15D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
265865
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
93165
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.26
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
149469
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
187733
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
629306
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
530704
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1181000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
580000
kprx Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Granted In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
1184000
kprx Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Granted In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
973000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y7M20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P2Y1M13D
CY2020Q3 kprx Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
0
CY2021Q3 kprx Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
0
kprx Cease Payments Not Yet Paid Based On Prevailing Financial Market Conditions
CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions
0.10
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
54841
kprx Operating Lease Interest On Lease Liabilities
OperatingLeaseInterestOnLeaseLiabilities
160881
CY2020Q3 kprx Operating Lease Interest On Lease Liabilities
OperatingLeaseInterestOnLeaseLiabilities
43195
kprx Operating Lease Interest On Lease Liabilities
OperatingLeaseInterestOnLeaseLiabilities
129585
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
55131
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
133788
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
95461
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25163
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
259217
CY2021Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
25905
CY2021Q3 kprx Defined Benefit Plan Contributions By Employer Accrued
DefinedBenefitPlanContributionsByEmployerAccrued
15251

Files In Submission

Name View Source Status
0001410578-21-000215-index-headers.html Edgar Link pending
0001410578-21-000215-index.html Edgar Link pending
0001410578-21-000215.txt Edgar Link pending
0001410578-21-000215-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kprx-20210930.xsd Edgar Link pending
kprx-20210930x10q.htm Edgar Link pending
kprx-20210930x10q_htm.xml Edgar Link completed
kprx-20210930xex31d1.htm Edgar Link pending
kprx-20210930xex31d2.htm Edgar Link pending
kprx-20210930xex32d1.htm Edgar Link pending
kprx-20210930xex32d2.htm Edgar Link pending
kprx-20210930_cal.xml Edgar Link unprocessable
kprx-20210930_def.xml Edgar Link unprocessable
kprx-20210930_lab.xml Edgar Link unprocessable
kprx-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending